Stock Price Quote

STRIDES PHARMA SCIENCE LTD.

NSE : STARBSE : 532531ISIN CODE : INE939A01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE1002.10-34.05 (-3.29 %)
PREV CLOSE ( ) 1036.15
OPEN PRICE ( ) 1011.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4526
TODAY'S LOW / HIGH ( )1000.00 1039.60
52 WK LOW / HIGH ( )769.6 1260.1
NSE1002.20-33.7 (-3.25 %)
PREV CLOSE( ) 1035.90
OPEN PRICE ( ) 1033.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1002.20 (68)
VOLUME 198743
TODAY'S LOW / HIGH( ) 1000.00 1039.90
52 WK LOW / HIGH ( )768.65 1260.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1990
Management Info
Arun Kumar - Chairman Badree Komandur - Managing Director
Registered Office

Address Cyberone, Unit No. 902,Plot No - 4 & 6,Sector 30 A, Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022-27892924 / 3199

Email corpcomm@strides.com

Website www.strides.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

30Oct Strides Pharma Science informs about a
Pursuant to Regulations 30 and 46 of the SEBI (Listing Obligations and D..
12Sep USFDA concludes cGMP inspection at for
United States Food and Drug Administration (USFDA) has concluded a routi..
20Aug Strides Pharma secures EIR from USFDA
Strides Pharma Science has secured Establishment Inspection Report (EIR)..
20Aug Strides Pharma soars on securing EIR f
Strides Pharma Science is currently trading at Rs. 991.05, up by 34.05 p..
20Jul Strides Pharma Science informs about r
Strides Pharma Science has informed that the 35th Annual General Meeting..

Financials

in Millions
QTR Sep 26 ANNUAL 26
Net Profit92.63000000000091836.35
Gross Profit 172.300000000001 2031.01
Operating Profit 728.0000000000014081.07
Net Sales 6599.0721801.35

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Divi's Laboratories (BSE)
peergroup  11570.00 (4.42%)
M.Cap ( in Cr)307147.15
Neuland Laboratories (BSE)
peergroup  20323.05 (2.25%)
M.Cap ( in Cr)26074.25
Gland Pharma (BSE)
peergroup  3301.35 (5.60%)
M.Cap ( in Cr)54475.86
Glaxosmithkline Phar (BSE)
peergroup  2710.85 (6.77%)
M.Cap ( in Cr)45923.43
Kwality Pharma (BSE)
peergroup  3856.75 (4.40%)
M.Cap ( in Cr)4001.84

Shareholding Pattern

FI/BANKS/INSURANCE 3.55%
PROMOTERS 29%
NON-INSTITUTION 27.51%
MUTUAL FUNDS/UTI 10.31%
GOVERNMENT 0.01%
FII 0%

About Strides Pharma Science Ltd.

Strides Pharma Science Ltd. was incorporated in the year 1990. Its today's share price is 1002.1. Its current market capitalisation stands at Rs 9237.38 Cr. In the latest quarter, company has reported Gross Sales of Rs. 21801.35 Cr and Total Income of Rs.23861.73 Cr. The company's management includes Ramaraju PVS, Aditya Kumar, Badree Komandur, Subir Chakraborty, Venkata Seetharama Raju Pakalapati, Ameet Hariani, Homi Rustam Khusrokhan, Mukta Arora, Kausalya Santhanam, Arun Kumar, Manjula Ramamurthy.

It is listed on the BSE with a BSE Code of 532531 , NSE with an NSE Symbol of STAR and ISIN of INE939A01011. It's Registered office is at Cyberone, Unit No. 902,Plot No - 4 & 6,Sector 30 A, VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Deloitte Haskins & Sells, Deloittee Haskins & Sells, Shivadas Kallianpur & Associates, SR Batliboi & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.